2 active not recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 2 |
Follow Biliary Atresia: new trials by email Literature Review of Biliary Atresia trials Research Report on Biliary Atresia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Maralixibat, Placebo - Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Phase 3 | Active not recruiting | Mirum Pharmaceuticals, Inc. | 90 | 2024-10-14 | 2026-10-06 |
| An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia Odevixibat - Biliary Atresia | Phase 3 | Active not recruiting | Albireo, an Ipsen Company | 180 | 2022-07-05 | 2026-10-23 |
Cholangitis, Sclerosing (1) · Pruritus (1)
Bile Duct Diseases (2) · Biliary Tract Diseases (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Abnormalities (2) · Digestive System Diseases (2) · Cholangitis (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Skin Diseases (1) · Skin Manifestations (1) · Skin and Connective Tissue Diseases (1)
maralixibat (1) · odevixibat (1)
Albireo, an Ipsen Company (1) · Mirum Pharmaceuticals, Inc. (1)
Canada (2) · France (2) · Germany (2) · Italy (2) · Poland (2) · Spain (2) · United States (2) · Australia (1) · Brazil (1) · China (1) · Lebanon (1) · Malaysia (1) · Netherlands (1) · New Zealand (1) · South Korea (1)